Trial · NCT02979899
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival of Patients With Unresectable Angiosarcoma | TRC105 + Votrient | PFS by RECIST 1.1 | 4.2 | 95% Confidence Interval 2.8 to 8.3 | months |
| Progression Free Survival of Patients With Unresectable Angiosarcoma | Votrient | PFS by RECIST 1.1 | 4.3 | 95% Confidence Interval 2.9 to NA | months |
| Progression Free Survival of Patients With Unresectable Angiosarcoma | TRC105 + Votrient | PFS by Investigator Assessment | 3.5 | 95% Confidence Interval 2.6 to 5.5 | months |
| Progression Free Survival of Patients With Unresectable Angiosarcoma | Votrient | PFS by Investigator Assessment | 2.9 | 95% Confidence Interval 2.6 to 4.1 | months |
| Objective Response Rate of Patients With Unresectable Angiosarcoma | TRC105 + Votrient | 3 | Participants | ||
| Objective Response Rate of Patients With Unresectable Angiosarcoma | Votrient | 8 | Participants | ||
| Overall Survival of Patients With Unresectable Angiosarcoma | TRC105 + Votrient | 17 | Participants | ||
| Overall Survival of Patients With Unresectable Angiosarcoma | Votrient | 19 | Participants | ||
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | TRC105 + Votrient | EORTC QLQ-C30 Health Score at Screening | 5 | Full Range 1 to 7 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | Votrient | EORTC QLQ-C30 Health Score at Screening | 5 | Full Range 1 to 7 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | TRC105 + Votrient | EQ-5D-5L Health Score at Screening | 75 | Full Range 5 to 100 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | Votrient | EQ-5D-5L Health Score at Screening | 75 | Full Range 20 to 100 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | TRC105 + Votrient | EORTC QLQ-C30 Health Score at Cycle 3 Day 1 | 4 | Full Range 1 to 6 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | Votrient | EORTC QLQ-C30 Health Score at Cycle 3 Day 1 | 5 | Full Range 1 to 6 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | TRC105 + Votrient | EQ-5D-5L Health Score at Cycle 3 Day 1 | 70 | Full Range 20 to 100 | units on a scale |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | Votrient | EQ-5D-5L Health Score at Cycle 3 Day 1 | 70 | Full Range 20 to 97 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02979899/results